Use of In Vivo and In Vitro Data to Derive a Chronic Reference Value for Crotonaldehyde Based on Relative Potency to...

Area of Science:

• Environmental toxicology
• Chemical risk assessment
• Inhalation exposure studies

Background:

• Limited toxicity data for crotonaldehyde (CRO) necessitated a novel assessment approach.
• Crotonaldehyde and acrolein share similar modes of action as α,β-unsaturated carbonyls.

Purpose of the Study:

• To derive a chronic inhalation noncancer toxicity reference value (ReV) for crotonaldehyde (CRO).
• To utilize a relative potency factor (RPF) approach with acrolein as the index chemical due to data limitations for CRO.

Main Methods:

• Calculated a CRO:acrolein RPF using in vivo data (respiratory depression and lethality) from studies measuring both chemicals.
• Utilized in vitro cytotoxicity data (propidium iodide and MTT assays) to support the in vivo RPF.
• Multiplied the established chronic ReV for acrolein by the calculated RPF to determine the CRO ReV.

Main Results:

• An in vivo RPF of 3 was calculated for CRO relative to acrolein.
• In vitro data supported the in vivo RPF, also yielding an RPF of 3.
• The derived chronic ReV for CRO is 3.6 ppb (10 μg/m³).

Conclusions:

• The established ReV for crotonaldehyde is protective against adverse health effects from chronic ambient air exposure.
• The RPF approach using acrolein as an index chemical proved effective for assessing CRO toxicity.
• This study provides a critical benchmark for environmental health standards related to crotonaldehyde.